Financial
Listed (300676.SZ).
Latest full-year results not yet captured by HSH.
BGI Genomics
HQ China · Asia-Pacific
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Not assessed
Customer rating
No reviews yet
Financial health
Band: Not assessedListed: 300676.SZ
Listed (300676.SZ).
Latest full-year results not yet captured by HSH.
Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
Oct 2026: the US Department of Homeland Security added BGI Genomics to the Uyghur Forced Labor Prevention Act Entity List, banning imports, alleging it helped collect genetic material used to track persecuted minorities; BGI denies the allegations.
Cyber & information governance
Oct 2026: in its import ban, US DHS alleged BGI companies helped collect genetic material used to track ethnic minorities, which China and BGI deny. No confirmed data breach involving BGI Genomics found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Regulatory & clinical safety
Dec 2025: the US BIOSECURE Act became law, restricting US federal contracts and grants involving 'biotechnology companies of concern'; legal commentary identifies BGI as covered via the Pentagon's 1260H list. No product recalls or safety notices found.
Contract performance
No notable contract go-lives, terminations or customer disputes involving BGI Genomics found in HSH's search of the last 24 months.
Competitors
No competitors linked yet.